The place of Glucagon-like 1 peptide receptor agonists (GLP-1RAs) in the new NICE guidelines – what is going on?
Keywords:National Institute for Health and Care Excellence (NICE), NICE guideline (NG) 28, Glucagon-like 1 peptide receptor agonists (GLP-1RAs)
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41(2):255-323. https://doi.org/10.1093/eurheartj/ehz486
Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020;43(2):487-93. https://doi.org/10.2337/dci19-0066
American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45(Suppl 1):S125-S143. https://doi.org/10.2337/dc22-S009
Type 2 diabetes. NICE clinical guideline 66 (CG 66). Centre for Clinical Practice at NICE (UK), 28 May 2008.
Newer Agents for Blood Glucose Control in Type 2 Diabetes. NICE Clinical Guidelines (CG87). Centre for Clinical Practice at NICE (UK), 27 May 2009.
Type 2 diabetes in adults: management. NICE guideline (NG28). 02 December 2015.
O'Hare JP, Millar-Jones D, Hanif W, et al. The revised NICE draft guideline for type 2 diabetes: still a long way to go. Lancet Diabetes Endocrinol 2015;3(9):679-80. https://doi.org/10.1016/S2213-8587(15)00288-0
Liraglutide for the treatment of type 2 diabetes mellitus. NICE Technology appraisal guidance (TA203), 27 October 2010.
Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes. NICE Technology appraisal guidance (TA248), 22 February 2012.
Type 2 diabetes: lixisenatide. Evidence summary (ESNM26), 24 September 2013.
Zinman B, Wanner C, Lachin JM, et al. Empagliﬂozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015 Nov 26;373(22):2117-28. https://doi.org/10.1056/NEJMoa1504720
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375(4):311-22. https://doi.org/10.1056/NEJMoa1603827
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375(19): 1834-44. https://doi.org/10.1056/NEJMoa1607141
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394(10193):121-30. https://doi.org/10.1016/S0140-6736(19)31149-3
Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018;392(10157):1519-29. https://doi.org/10.1016/S0140-6736(18)32261-X
Type 2 diabetes in adults: management. NICE guideline (NG28). Updated 31 March 2012
Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab 2015;6(1):19-28. https://doi.org/10.1177/2042018814559725
Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.